Free tool
FAERS Monitor: Hiprex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017681 or its brand name (Hiprex, Methenamine Hippurate). Reports on generic versions are filed under their own applications.
Reports
1,289
Serious
736
57% of reports
Hospitalization
353
Death reported
82
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- urinary tract infection169
- diarrhoea83
- drug ineffective83
- nausea83
- fatigue78
- fall74
- headache70
- dizziness66
- death57
- product dose omission issue57
- off label use52
- pneumonia51
- asthenia50
- dyspnoea50
- malaise47
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 10 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 13 |
| 2013 | 9 |
| 2014 | 25 |
| 2015 | 52 |
| 2016 | 65 |
| 2017 | 58 |
| 2018 | 67 |
| 2019 | 72 |
| 2020 | 92 |
| 2021 | 91 |
| 2022 | 97 |
| 2023 | 115 |
| 2024 | 129 |
| 2025 | 180 |
| 2026 | 200 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,870 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| urinary tract infectionSignal | 169 | 16.2 | 14.1 | 2,409 |
| fallSignal | 74 | 3.6 | 2.9 | 140 |
| product dose omission issueSignal | 57 | 3.2 | 2.5 | 83 |
| pneumoniaSignal | 51 | 2.6 | 2.0 | 48 |
| astheniaSignal | 50 | 2.2 | 1.7 | 31 |
| dizzinessSignal | 66 | 2.2 | 1.7 | 41 |
| diarrhoeaSignal | 83 | 2.1 | 1.7 | 48 |
| headache | 70 | 1.8 | 1.5 | 26 |
| malaise | 47 | 1.7 | 1.3 | 15 |
| nausea | 83 | 1.7 | 1.4 | 25 |
| fatigue | 78 | 1.6 | 1.3 | 19 |
| dyspnoea | 50 | 1.4 | 1.1 | 6 |
| death | 57 | 1.1 | 0.8 | 0 |
| drug ineffective | 83 | 1.0 | 0.8 | 0 |
| off label use | 52 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.